Silence Therapeutics PLC Holding(s) in Company (7747P)
14 Ottobre 2019 - 11:40AM
UK Regulatory
TIDMSLN
RNS Number : 7747P
Silence Therapeutics PLC
14 October 2019
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible)(i)
1a. Identity of the issuer or the Silence Therapeutics Plc
underlying issuer of existing shares
to which voting rights are attached(ii)
:
--------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify)(iii) :
----
3. Details of person subject to the notification obligation(iv)
Name Robert Quested
City and country of registered office
(if applicable)
4. Full name of shareholder(s) (if different from 3)(v)
Name
--------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------
5. Date on which the threshold was 6 September 2019
crossed or reached(vi) :
--------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 11 October 2019
--------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer(vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 11.33% 0.00% 11.33% 78,327,279
------------------ --------------------- -------------- --------------------
Position of
previous notification
(if
applicable) 3.76% 0.00% 3.76%
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached(viii)
A: Voting rights attached to shares
Class/type of Number of voting rights(ix) % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) Directive
(DTR5.1) (DTR5.2.1) 2004/109/EC)
(DTR5.2.1)
-----------------------
Ordinary
GB00B9GTXM62 8,871,417 11.33%
------------------------ ----------------------- ------------------------------------ ------------------
SUBTOTAL 8. A 8,871,417 11.33%
------------------------------------------------- --------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of financial Expiration Exercise/ Number of voting rights % of voting
instrument date(x) Conversion Period(xi) that may be acquired rights
if the instrument
is
exercised/converted.
------------ ------------------------- ---------------------------------------------- ------------------
SUBTOTAL 8. B 1
------------------------- ---------------------------------------------- ------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical Number of % of voting
financial date(x) Conversion Period or cash voting rights rights
instrument (xi) settlement(xii)
--------------------- ------------------------- ------------------------- -------------------
SUBTOTAL
8.B.2
------------------------- -------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled X
by any natural person or legal entity and does not control any
other undertaking(s) holding directly or indirectly an interest
in the (underlying) issuer(xiii)
Full chain of controlled undertakings through which the voting
rights and/or the
financial instruments are effectively held starting with the
ultimate controlling natural person or legal entity(xiv) (please
add additional rows as necessary)
Name(xv) % of voting % of voting rights Total of both
rights if it through financial if it equals
equals or is instruments if or is higher
higher than it equals or is than the notifiable
the notifiable higher than the threshold
threshold notifiable threshold
------------------ ----------------------------------- --------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
---------------------------------------------------------------
The number and % of voting rights held N/A
---------------------------------------------------------------
The date until which the voting rights N/A
will be held
---------------------------------------------------------------
11. Additional information(xvi)
Place of completion UK
Date of completion 14 October 2019
----------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLUSOKRKBARARA
(END) Dow Jones Newswires
October 14, 2019 05:40 ET (09:40 GMT)
Grafico Azioni Silence Therapeutics (LSE:SLN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Silence Therapeutics (LSE:SLN)
Storico
Da Apr 2023 a Apr 2024
Notizie in Tempo Reale relative a Silence Therapeutics Plc (Borsa di Londra): 0 articoli recenti
Più Silence Therapeutics Plc Articoli Notizie